Please login to the form below

Not currently logged in
Email:
Password:

Paul Navarre moves from Allergan to Ferring Pharmaceuticals

Takes up CEO role at its Ferring Holding subsidiary

Paul NavarreFerring Pharmaceuticals has appointed Paul Navarre as CEO of Ferring Holding Inc - a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharma company - in a role that will see him assume responsibility for all of the group’s activities including commercial operations, clinical development and manufacturing.

Navarre has more than 25 years’ experience in the pharmaceuticals and consumer good industries and joins from Allergan, where he was president of Allergan International and managed a $3bn speciality care business covering dermatology, ophthalmology, urology and neurosciences.

Before joining Allergan, Navarre spent 15 years at Procter & Gamble holding positions in France, USA, Switzerland, Italy and the UK.

He said: “Ferring is a fast growing pharmaceutical company with a unique culture centred on people and patients.

“I am very excited to lead this organisation into the next phase of its development.”

As CEO, Navarre will report to the board of directors chaired by Michel Pettigrew, president of the executive board and chief operating officer of Ferring Group.

Pettigrew said: “Paul’s extensive pharmaceutical speciality care experience and proven international leadership skills will help him take our successful US operations to the next level, pursuing our rapid extension.”

Navarre succeeds Aaron Graff who has been appointed to a global role as executive vice president, chief commercial officer and member of the Ferring Group executive board.

6th June 2017

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Genesis Research

Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...

Latest intelligence

Biosimilars and beyond: innovating for improved patient outcomes
How Europe’s biosimilar landscape has rapidly evolved over the last two decades, bringing biological medicines to more patients than ever before...
World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...